NetworkNewsWire Editorial Coverage NEW YORK, July 9, 2025 /PRNewswire/ -- Each year, approximately 20 million people are diagnosed with cancer, and nearly 10 million lives are lost to the ...

Each year, approximately 20 million people are diagnosed with cancer, and nearly 10 million lives are lost to the disease ...

Vertex Pharmaceuticals’ cystic fibrosis (CF) therapy Alyftrek (deutivacaftor/tezacaftor/vanzacaftor) has been approved by the European Commission (EC).

PGIM Jennison Health Sciences Fund’s Q1 2025 letter highlights mixed sector returns, with Vertex Pharmaceuticals in focus.

Vertex Pharmaceuticals Inc. closed 10.29% short of its 52-week high of $519.88, which the company achieved on November 8th.

Trump’s “big beautiful” bill will also affect the pharmaceutical industry, while AI startups have pulled in the majority of ...

PGIM Jennison Health Sciences Fund released its first quarter 2025 investor letter. A copy of the letter can be downloaded ...

China Universal Asset Management trimmed its Vertex Pharmaceuticals stake by 6.7% in Q1, selling 3,515 shares and retaining ...

New stem cell therapy offers hope for type 1 diabetes, freeing patients from insulin. Learn why diverse clinical trial ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Want to invest in artificial intelligence (AI), cloud computing, digital media, and e-commerce in one fell swoop? You could ...

There are many promising corporations that investors can buy on a dip due to recent market volatility or company-specific ...